Scarica l'app Stockscreener
1.13
3.42%
-0.04
Dopo l'orario di chiusura:
1.15
0.02
+1.77%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CHRS Giù?
Forum
Previsione
Precedente Chiudi:
$1.17
Aprire:
$1.17
Volume 24 ore:
1.22M
Relative Volume:
1.08
Capitalizzazione di mercato:
$174.59M
Reddito:
$46.88M
Utile/perdita netta:
$-172.66M
Rapporto P/E:
-0.9068
EPS:
-1.2461
Flusso di cassa netto:
$-170.57M
1 W Prestazione:
-16.30%
1M Prestazione:
-17.52%
6M Prestazione:
-36.16%
1 anno Prestazione:
-22.07%
Intervallo 1D:
$1.13
$1.185
Intervallo di 1 settimana:
$1.13
$1.43
Portata 52W:
$1.09
$2.6158
Coherus Oncology Inc Stock (CHRS) Company Profile
Nome
Coherus Oncology Inc
Settore
Industria
Telefono
(650) 649-3530
Indirizzo
C/O DENNIS M. LANFEAR, REDWOOD CITY, CA
Compare CHRS vs VRTX, REGN, MRNA, ARGX, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CHRS
Coherus Oncology Inc
|
1.13 | 174.59M | 46.88M | -172.66M | -170.57M | -1.2461 |
VRTX
Vertex Pharmaceuticals Inc
|
526.19 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
788.04 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
198.88 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
959.49 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
204.97 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Coherus Oncology Inc Stock (CHRS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-23 | Iniziato | Oppenheimer | Outperform |
| 2025-09-04 | Aggiornamento | Maxim Group | Hold → Buy |
| 2024-08-16 | Downgrade | UBS | Buy → Neutral |
| 2023-11-17 | Iniziato | Robert W. Baird | Outperform |
| 2023-11-08 | Downgrade | Maxim Group | Buy → Hold |
| 2023-07-24 | Iniziato | Citigroup | Buy |
| 2023-05-01 | Iniziato | Truist | Buy |
| 2023-03-28 | Aggiornamento | UBS | Neutral → Buy |
| 2022-06-14 | Iniziato | UBS | Neutral |
| 2022-03-07 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-07-16 | Iniziato | BofA Securities | Neutral |
| 2020-04-17 | Iniziato | SunTrust | Buy |
| 2019-08-13 | Iniziato | Mizuho | Buy |
| 2019-08-02 | Reiterato | H.C. Wainwright | Buy |
| 2019-08-02 | Reiterato | Maxim Group | Buy |
| 2019-06-11 | Iniziato | Barclays | Overweight |
| 2019-05-07 | Iniziato | H.C. Wainwright | Buy |
| 2018-08-28 | Iniziato | H.C. Wainwright | Buy |
| 2018-03-09 | Reiterato | Maxim Group | Buy |
| 2017-08-08 | Reiterato | JP Morgan | Overweight |
| 2017-06-13 | Reiterato | Maxim Group | Buy |
| 2017-05-05 | Iniziato | BMO Capital Markets | Outperform |
| 2016-10-19 | Iniziato | Robert W. Baird | Outperform |
| 2016-09-07 | Iniziato | Maxim Group | Buy |
| 2016-07-27 | Iniziato | Citigroup | Buy |
| 2016-01-20 | Iniziato | Credit Suisse | Outperform |
Mostra tutto
Coherus Oncology Inc Borsa (CHRS) Ultime notizie
Eligible shareholders may share proceeds from Coherus' assets tied to similar medicines. The sale process has begun. - stocktitan.net
Coherus Oncology Shares Down on Plans to Sell Biosimilar Assets - Moomoo
Coherus initiates sale of legacy biosimilars assets - Investing.com
Coherus Oncology Starts Process to Sell Remaining Biosimilar Assets - marketscreener.com
Coherus initiates sale of legacy biosimilars assets By Investing.com - Investing.com Nigeria
Coherus (CHRS) Stock: Slides -0.82%, Support at $1.15 2026-09-17Moving Average Ribbon - careplusvn.com
Coherus at Morgan Stanley healthcare conference: oncology push gains traction - Investing.com Canada
CHRS: Strong commercial growth and promising oncology pipeline drive optimism for future milestones - TradingView
CHRS: Strong commercial execution and promising oncology pipeline position the company for growth - TradingView
Transcript : Coherus Oncology, Inc. Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-16-2026 12 - marketscreener.com
CHRS: Innovative oncology focus drives pipeline progress, with key data readouts expected by year-end - TradingView
CHRS: Strategic oncology focus drives revenue growth and key clinical milestones, with major data readouts ahead - TradingView
CHRS: Pipeline advances and strong LOQTORZI sales position for growth, with major data readouts ahead - TradingView
Coherus Oncology at 2026 Global Healthcare Conference: pipeline, sales push - Investing.com Canada
Coherus BioSciences stock reacts to BlackRock stake and latest oncology focus - ad-hoc-news.de
CHRS Q2 2026 Earnings: Narrower-than-Expected Loss Drives 2.59% Share GainPost-Earnings Reaction - vinanet.vn
Coherus to Participate in Upcoming Investor Conferences - Yahoo Finance
Coherus Oncology files $50M at-the-market sales agreement with Leerink Partners - TradingView
Coherus (CHRS) Quarter in Focus: The Bottom-Line Figure Beats Its Comparison at the Close; Closing Reaction: Shares Finish 4.23% Down for the Current SessionEarnings Growth Analysis - vinanet.vn
Coherus: 'Hold' On Several Tagmokitug 2026 Catalysts And Casdozokitug HCC Drug Development - Seeking Alpha
Coherus (CHRS) Q2 2026 Results: Reported EPS Tops Expectations in Latest Trading; Market Reaction: Shares Finish 16.52% UpEarnings Power Value - vinanet.vn
Form 8K Coherus BioSciences Inc For: 17 August By Investing.com - Investing.com India
CHRS Looks 10.6% Overvalued on GF Value™ - GuruFocus
Coherus Oncology Secures $55M Term Loan, Extends Debt Maturity to 2031 - Minichart
Coherus Declares Special Dividend of Biosimilar Contingent Value Rights, Payable Oct. 7 to Holders of Record Sept. 30 - marketscreener.com
Coherus Oncology Announces Special Dividend Of Biosimilar Contingent Value Rights - tradingview.com
Coherus Oncology Announces Special Dividend of Biosimilar Contingent Value Rights - GlobeNewswire
Coherus will give eligible holders rights to cash from former assets—but they may expire unpaid - Stock Titan
Coherus Oncology, Inc., Coherus Intermediate Corp, Surface Oncology, LLC, and InteKrin Therapeutics Inc., Enter into Loan and Security Agreement - marketscreener.com
Q3 EPS Estimates for Coherus Oncology Cut by HC Wainwright - MarketBeat
Coherus Oncology (CHRS) Q2 2026 Earnings Call Transcript - The Globe and Mail
ETFs Investing in Coherus Oncology, Inc. Stocks - TradingView
CHRS Maintained by Guggenheim -- Price Target Lowered to $10.00 - GuruFocus
Coherus Oncology Is Maintained at Buy by Guggenheim - Moomoo
Earnings call transcript: Coherus Oncology posts Q2 2026 EPS beat, shares fall - Investing.com Nigeria
H.C. Wainwright Maintains Coherus Oncology(CHRS.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Coherus Oncology, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Coherus Oncology Reports Second Quarter 2026 Financial Results and Provides Business Update - The Manila Times
Coherus Oncology Inc (CHRS) (Q2 2026) Earnings Call Highlights: - GuruFocus
Coherus Oncology Inc (CHRS) (Q2 2026) Earnings Call Highlights: LOQTORZI Growth and Pipeline ... - finance.yahoo.com
Coherus Oncology, Inc. 2026 Q2 10-Q Highlights: Financials, Risks, and Forward-Looking Statements for Investors - Minichart
Coherus Oncology Q2 2026 Results: LOQTORZI Revenue Growth, Pipeline Progress, and Financial Update - Minichart
CHRS Looks 83.5% Overvalued on GF Value™ - GuruFocus
Coherus Oncology Q2 Earnings Call Highlights - MarketBeat
Coherus Oncology : Reports Second Quarter 2026 Financial Results and Provides Business Update - marketscreener.com
Coherus Oncology (NASDAQ:CHRS) Announces Quarterly Earnings Results - MarketBeat
CHRS: LOQTORZI sales rose 15% in Q2, with key clinical data readouts expected later in 2026 - TradingView
Coherus Oncology Inc reports results for the quarter ended June 30Earnings Summary - tradingview.com
Is Coherus Oncology Inc (CHRS) Worth the Investment After Q2 Ear - GuruFocus
Coherus Oncology (CHRS) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
Coherus Oncology (NASDAQ: CHRS) posts Q2 2026 loss amid growing LOQTORZI revenue - Stock Titan
Coherus Oncology Inc Azioni (CHRS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.06%
2.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):